MarketBeat
18 Nov 2026, 07:13 UTC · 2h ago
DexCom Sees Record New Patients in 2026 as Medicare Coverage Decision Looms
Impact · against what's priced in
DXCM outlook raises are moderately positive as they signal FY2026 EPS beats, though long-term margin targets are already baked into the current valuation. The potential Medicare expansion remains a future catalyst that the market is currently discounting, with material revenue impact delayed until H2 2027.
- DXCM+0.30
Not in the price yet
- The price assumes
Revenue growth of roughly 11-13% annually
Raising the 2026 outlook to the top end of the range suggests a beat relative to the 11.7% CAGR the price currently assumes, likely triggering upward EPS revisions.
What DXCM's price assumes · Sep 23





